<DOC>
	<DOCNO>NCT00267696</DOCNO>
	<brief_summary>The purpose study test effectiveness , safety tolerability drug combination : gemcitabine , carboplatin bevacizumab patient diagnose platinum sensitive recurrent ovarian cancer , fallopian tube primary peritoneal cancer .</brief_summary>
	<brief_title>Study Gemcitabine/Carboplatin/Bevacizumab Treat Ovarian , Fallopian Tube Primary Peritoneal Cancer</brief_title>
	<detailed_description>In study participant receive drug combination gemcitabine/carboplatin bevacizumab every two week . As long evidence tumor grow participant experience unacceptable side effect , participation continue 2 year . The study do find effectiveness , safety tolerability combination chemotherapy drug . Bevacizumab affect growth new blood vessel body . It part study see stop growth new blood vessel body help stop growth spread cancer . The two chemotherapy drug , gemcitabine carboplatin , currently use together treatment ovarian cancer .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Cancer ovary , fallopian tube abdominal lining come back 6 month last platinum base chemotherapy treatment . Disease must detect CT CA125 level must elevate cancerous ascites must present . History least one therapy platinum base chemotherapy . Participation another experimental drug study Heart disease high blood pressure History stroke within past 6 month Vascular disease , bleed problem Brain cancer Major Surgical Procedure within 28 day prior start date Minor surgical procedure within 7 day prior start date Pregnant lactate Abdominal bowel problem like bleed History abdominal fistula , GI perforation Intraabdominal abscess Serious , nonhealing wound , ulcer bone fracture Acute hepatitis Active infection require antibiotic Inability comply study follow procedure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>platinum sensitive cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cancer</keyword>
</DOC>